In ovarian cancer cells, VEGFR2 blockade suppressed glycolysis by inhibiting the VEGFR2-AKT1-GSK3β-SOX5-GLUT4 signaling pathway [41]. This evidence concerns the gene AKT1 and ovarian cancer.